Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female from 9 to 15 years old.~* Good physical health.~Exclusion Criteria:~* Known allergy to any vaccine component.~* History of severe allergic reaction.~* Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.~* Pregnant subject.~* Immunocompromised or immunodeficient subject.~* Splenectomy.~* Receipt of medication / vaccine that may interfere with study assessment.~* Fever~* History of a positive test for HPV, prior receipt of HPV vaccine or prior participation to HPV trial.~* Any condition that might interfere with study assessment.

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- V503 (Type: EXPERIMENTAL): 9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
- GARDASIL (Type: ACTIVE_COMPARATOR): Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6

Based on this trial design, predict the completion outcome and termination type (if applicable).